X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian markets remain lackluster 
(Mon, 27 Oct 11:30 am) 
 
After opening positive, the Indian Indices have continued to trade above the dotted line in the morning trading session. However, majority of sectoral indices are trading in red with realty and oil and gas sector stocks being the leading losers in the pack. Capital goods stocks and banking stocks were among the leading gainers.

The BSE-Sensex is trading up 22 points. The NSE-Nifty is trading up 6 points. The BSE Mid Cap index is trading down 0.23% while the BSE Small Cap index is trading up 0.23%. The rupee is trading at 61.23 to the US dollar.

Indian pharma stocks are trading mixed with, Piramal Enterprise and Orchid chemicals being the leading gainers in the pack, while Natco pharma and Panacea biotech leading among the losers. As per the financial daily, Ranbaxy Laboratories might lose the six month exclusivity on its generic launch of Nexium in US. Nexium is a blockbuster drug worth market size of US$ 4 Bn and used for the treatment of heartburn. Ranbaxy is holds first to file status and is entitled for 180-days exclusivity in US. However, Ranbaxy might lose its 180-days exclusivity if it fails to get approval by Nov 2014. Reportedly, The ban on selling drugs manufactured at the Punjab and Himachal units of Ranbaxy has resulted in the regulatory delay. In past also, Ranbaxy has faced challenges in getting approvals for various products including for its FTFs (First to file). Due to this, the company had also shared its exclusivity with other generic companies. Among its four manufacturing facilities only one is currently US approved located in Ohm US and others are under USFDA scanner. The company, which is in the process of being acquired by Sun Pharma, is preparing to make the generic version of Nexium from its plant in the US.

Majority of the software stocks are trading weak with HCL Technologies and Wipro leading the losers. India's second largest software firm Infosys, under CEO Vishal Sikka, is undergoing a major management overhaul. Senior management attrition was the key concern regarding the company. However, the problems are seemingly being addressed. Several senior and mid management positions have already been filled. The CEO has also convinced many of his former colleagues at SAP to join him at Infosys. In 2QFY15, the company had recruited over 3,000 professionals from several global corporations to provide leadership for the new teams that are being formed within the firm. This massive re-organisation is part of the plan to help transform Infosys into a next generation IT services company.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian markets remain lackluster". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Aug 23, 2017 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS